Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Average Rating of "Reduce" from Analysts

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) have received a consensus rating of "Reduce" from the nine research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating and eight have given a hold rating to the company.

Separately, Bank of America upgraded shares of Bayer Aktiengesellschaft from an "underperform" rating to a "neutral" rating in a research report on Friday, September 6th.

Bayer Aktiengesellschaft Stock Performance

Shares of OTCMKTS BAYRY traded down $0.14 during mid-day trading on Thursday, hitting $6.81. The company had a trading volume of 1,378,174 shares, compared to its average volume of 1,334,285. The business's 50-day simple moving average is $7.65 and its 200-day simple moving average is $7.48. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.27 and a quick ratio of 0.86. The firm has a market cap of $26.76 billion, a P/E ratio of -7.83 and a beta of 1.08. Bayer Aktiengesellschaft has a 12 month low of $6.76 and a 12 month high of $11.34.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported $0.25 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.25. Bayer Aktiengesellschaft had a positive return on equity of 16.96% and a negative net margin of 2.74%. The business had revenue of $12 billion during the quarter. As a group, analysts predict that Bayer Aktiengesellschaft will post 1.38 earnings per share for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.